2024
Medicare Local Coverage Determinations: Evidence Quality Is Stronger For Covered Indications
Moneer O, Mooghali M, Moosa K, Ramachandran R, Ross J, Dhruva S. Medicare Local Coverage Determinations: Evidence Quality Is Stronger For Covered Indications. Health Affairs 2024, 43: 1712-1718. PMID: 39626147, DOI: 10.1377/hlthaff.2024.00182.Peer-Reviewed Original ResearchConceptsCentury Cures ActLocal coverage determinationsCures ActQuality of evidenceHigh-risk devicesCoverage decisionsPatient ageClinical evidenceClinical studiesCoverage determinationMedical literatureTherapeutic drugsSixty-fiveCoverage databaseEvidence strengthEvidence qualityEvidence summaryActMedicare coverage decisionsMedicare beneficiary population
2021
Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation
Benning TJ, Shah ND, Inselman JW, Van Houten HK, Ross JS, Wyatt KD. Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation. Clinical Trials 2021, 18: 732-740. PMID: 34269090, PMCID: PMC10119689, DOI: 10.1177/17407745211030683.Peer-Reviewed Original ResearchConceptsPediatric Research Equity ActClinical trialsBest PharmaceuticalsOncology drugsDrug utilizationPediatric indicationsLabel changesPediatric-specific evidenceAdministrative claims databasePediatric Hematology/OncologyQuality of evidenceDrug labelling changesHematology/oncologyDrug utilization ratesNew pediatric indicationsLow methodological rigorClaims databaseComparator groupPediatric utilizationTrial characteristicsBACKGROUND/Pediatric useMonthly utilization ratesDrug safetyStudy design